{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The MTD/RP2D will be defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy among 6 toxicity-evaluable patients. The frequency of cycle 1 dose limiting toxicities will be summarized by dose level among patients in the dose escalation part of the study.","groups":[{"description":"Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, who receive entinostat on Days 1, 8, 15, and 22 of a 28-day cycle","id":"OG000","title":"Treatment (Entinostat)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat","type":"PRIMARY","unitOfMeasure":"mg/m²"}